FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385581275> ?p ?o ?g. }

• W4385581275 abstract "Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished. We examined the cost-per-outcome implications of utilizing dapagliflozin as compared to empagliflozin for prevention of renal and cardiovascular events in CKD patients. Methods: For calculation of preventable events we divided the allocated budget by the cost needed to treat (CNT) for preventing a single renal or cardiovascular event. CNT was derived by multiplying the annualized number needed to treat (aNNT) by the annual therapy cost. The aNNTs were determined based on data from the DAPA-CKD and EMPEROR-KIDNEY trials. The budget limit was defined based on the threshold recommended by the United States' Institute for Clinical and Economic Review. Results: The aNNT was 42 both dapagliflozin (95% confidence interval [CI]: 34-59) and empagliflozin (CI: 33-66). The CNT estimates for the prevention of one primary event for dapagliflozin and empagliflozin were comparable at $201,911 (CI: $163,452-$283,636) and $209,664 (CI: $164,736-$329,472), respectively. However, diabetic patients had a higher CNT with dapagliflozin ($201,911 [CI: $153,837-$346,133]) than empagliflozin ($134,784 [CI: $109,824-$214,656]), whereas non-diabetic patients had lower CNT for dapagliflozin ($197,103 [CI: $149,029-$346,133]) than empagliflozin ($394,368 [CI: $219,648-$7,093,632]). The CNT for preventing CKD progression was higher for dapagliflozin ($427,858 [CI: $307,673-$855,717]) than empagliflozin ($224,640 [CI: $169,728-$344,448]). For preventing cardiovascular death (CVD), the CNT was lower for dapagliflozin ($1,634,515 [CI: $740,339-∞]) than empagliflozin ($2,990,208 [CI: $1,193,088-∞]). Conclusion: Among patients with CKD, empagliflozin provides a better monetary value for preventing the composite renal and cardiovascular events in diabetic patients while dapagliflozin has a better value for non-diabetic patients. Dapagliflozin provides a better monetary value for the prevention of CVD, whereas empagliflozin has a better value for the prevention of CKD progression." @default.
• W4385581275 created "2023-08-05" @default.
• W4385581275 creator A5001874191 @default.
• W4385581275 creator A5002428432 @default.
• W4385581275 creator A5006966498 @default.
• W4385581275 creator A5010393245 @default.
• W4385581275 creator A5022167714 @default.
• W4385581275 creator A5030931326 @default.
• W4385581275 creator A5035639700 @default.
• W4385581275 creator A5058266202 @default.
• W4385581275 creator A5059868848 @default.
• W4385581275 date "2023-08-04" @default.
• W4385581275 modified "2023-09-25" @default.
• W4385581275 title "Dapagliflozin versus empagliflozin in patients with chronic kidney disease" @default.
• W4385581275 cites W1990040478 @default.
• W4385581275 cites W2069496858 @default.
• W4385581275 cites W2134855422 @default.
• W4385581275 cites W2146264128 @default.
• W4385581275 cites W2424539745 @default.
• W4385581275 cites W2621228814 @default.
• W4385581275 cites W2626446274 @default.
• W4385581275 cites W2751214186 @default.
• W4385581275 cites W2884144220 @default.
• W4385581275 cites W2900413769 @default.
• W4385581275 cites W2939222610 @default.
• W4385581275 cites W3004773997 @default.
• W4385581275 cites W3088173406 @default.
• W4385581275 cites W3185350835 @default.
• W4385581275 cites W3212142134 @default.
• W4385581275 cites W3214433244 @default.
• W4385581275 cites W4200592623 @default.
• W4385581275 cites W4205782428 @default.
• W4385581275 cites W4210858922 @default.
• W4385581275 cites W4229508150 @default.
• W4385581275 cites W4280585270 @default.
• W4385581275 cites W4287378212 @default.
• W4385581275 cites W4294879033 @default.
• W4385581275 cites W4306783500 @default.
• W4385581275 cites W4308060342 @default.
• W4385581275 cites W4308183941 @default.
• W4385581275 cites W4360778245 @default.
• W4385581275 cites W4367298758 @default.
• W4385581275 cites W4376132656 @default.
• W4385581275 cites W4376868506 @default.
• W4385581275 cites W4380564289 @default.
• W4385581275 cites W4383186345 @default.
• W4385581275 cites W4383301637 @default.
• W4385581275 doi "https://doi.org/10.3389/fphar.2023.1227199" @default.
• W4385581275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37601066" @default.
• W4385581275 hasPublicationYear "2023" @default.
• W4385581275 type Work @default.
• W4385581275 citedByCount "0" @default.
• W4385581275 crossrefType "journal-article" @default.
• W4385581275 hasAuthorship W4385581275A5001874191 @default.
• W4385581275 hasAuthorship W4385581275A5002428432 @default.
• W4385581275 hasAuthorship W4385581275A5006966498 @default.
• W4385581275 hasAuthorship W4385581275A5010393245 @default.
• W4385581275 hasAuthorship W4385581275A5022167714 @default.
• W4385581275 hasAuthorship W4385581275A5030931326 @default.
• W4385581275 hasAuthorship W4385581275A5035639700 @default.
• W4385581275 hasAuthorship W4385581275A5058266202 @default.
• W4385581275 hasAuthorship W4385581275A5059868848 @default.
• W4385581275 hasBestOaLocation W43855812751 @default.
• W4385581275 hasConcept C126322002 @default.
• W4385581275 hasConcept C126894567 @default.
• W4385581275 hasConcept C134018914 @default.
• W4385581275 hasConcept C166595027 @default.
• W4385581275 hasConcept C178790620 @default.
• W4385581275 hasConcept C185592680 @default.
• W4385581275 hasConcept C2775887513 @default.
• W4385581275 hasConcept C2777180221 @default.
• W4385581275 hasConcept C2777422806 @default.
• W4385581275 hasConcept C2777693530 @default.
• W4385581275 hasConcept C2778653478 @default.
• W4385581275 hasConcept C2779684741 @default.
• W4385581275 hasConcept C44249647 @default.
• W4385581275 hasConcept C555293320 @default.
• W4385581275 hasConcept C71924100 @default.
• W4385581275 hasConceptScore W4385581275C126322002 @default.
• W4385581275 hasConceptScore W4385581275C126894567 @default.
• W4385581275 hasConceptScore W4385581275C134018914 @default.
• W4385581275 hasConceptScore W4385581275C166595027 @default.
• W4385581275 hasConceptScore W4385581275C178790620 @default.
• W4385581275 hasConceptScore W4385581275C185592680 @default.
• W4385581275 hasConceptScore W4385581275C2775887513 @default.
• W4385581275 hasConceptScore W4385581275C2777180221 @default.
• W4385581275 hasConceptScore W4385581275C2777422806 @default.
• W4385581275 hasConceptScore W4385581275C2777693530 @default.
• W4385581275 hasConceptScore W4385581275C2778653478 @default.
• W4385581275 hasConceptScore W4385581275C2779684741 @default.
• W4385581275 hasConceptScore W4385581275C44249647 @default.
• W4385581275 hasConceptScore W4385581275C555293320 @default.
• W4385581275 hasConceptScore W4385581275C71924100 @default.
• W4385581275 hasLocation W43855812751 @default.
• W4385581275 hasLocation W43855812752 @default.
• W4385581275 hasOpenAccess W4385581275 @default.
• W4385581275 hasPrimaryLocation W43855812751 @default.
• W4385581275 hasRelatedWork W2199901734 @default.
• W4385581275 hasRelatedWork W2807204184 @default.
• W4385581275 hasRelatedWork W2948420741 @default.

• next